Imatinib Therapeutic Drug Monitoring

ARUP now offers a therapeutic drug monitoring (TDM) test for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients being treated with the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is a first-line treatment for CML and GIST.

Why Is This Testing Important?

Imatinib, when dosed according to TDM, yields a similar major molecular response (MMR) as second generation TKIs.1

TDM Can Improve Dose Optimization

Optimization Table

Figure 1. In a study of 1,910 CML samples, imatinib trough plasma concentration levels are shown according to total daily dose. At each dose, mean concentrations are stated and indicated by a horizontal line. The top and bottom of each box represent the 25th and 75th percentiles, and vertical lines indicate the standard deviation. The dotted line corresponds to the imatinib Cmin threshold (1002 ng/mL).2

Imatinib Testing

Before Ordering Imatinib

1. Patient should have had uninterrupted imatinib therapy for at least 29 days with no change in dose or treatment for at least 8 days.

2. Contact your existing lab provider and reference ARUP test code 3000539 to order.